{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:06:01Z","timestamp":1777421161126,"version":"3.51.4"},"publisher-location":"New York, NY","reference-count":50,"publisher":"Springer US","isbn-type":[{"value":"9781071627273","type":"print"},{"value":"9781071627280","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T00:00:00Z","timestamp":1664064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T00:00:00Z","timestamp":1664064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-2728-0_16","type":"book-chapter","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T13:04:32Z","timestamp":1664024672000},"page":"201-211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Endocannabinoid Metabolism and Transport as Drug Targets"],"prefix":"10.1007","author":[{"given":"Francesca","family":"Ciaramellano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Scipioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Maccarrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Oddi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,25]]},"reference":[{"key":"16_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1124\/PR.58.3.2","volume":"58","author":"P Pacher","year":"2006","unstructured":"Pacher P, B\u00e1tkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389. https:\/\/doi.org\/10.1124\/PR.58.3.2","journal-title":"Pharmacol Rev"},{"key":"16_CR2","first-page":"3704","volume":"7","author":"W-R Hu","year":"2014","unstructured":"Hu W-R, Lian Y-F, Peng L-X, Lei J-J, Deng C-C, Xu M, Feng Q-S, Chen L-Z, Bei J-X, Zeng Y-X (2014) Monoacylglycerol lipase promotes metastases in nasopharyngeal carcinoma. Int J Clin Exp Pathol 7:3704\u20133713","journal-title":"Int J Clin Exp Pathol"},{"key":"16_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1620\/TJEM.256.19","volume":"256","author":"X Gong","year":"2022","unstructured":"Gong X, Zheng X, Huang Y, Song W, Chen G, Chen T (2022) Monoacylglycerol lipase (MAGL) inhibition impedes the osteosarcoma progression by regulating epithelial mesenchymal transition. Tohoku J Exp Med 256:19\u201326. https:\/\/doi.org\/10.1620\/TJEM.256.19","journal-title":"Tohoku J Exp Med"},{"key":"16_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/J.NEUROPHARM.2021.108450","volume":"185","author":"D Kokona","year":"2021","unstructured":"Kokona D, Spyridakos D, Tzatzarakis M, Papadogkonaki S, Filidou E, Arvanitidis KI, Kolios G, Lamani M, Makriyannis A, Malamas MS et al (2021) The endocannabinoid 2-arachidonoylglycerol and dual ABHD6\/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity. Neuropharmacology 185:108450. https:\/\/doi.org\/10.1016\/J.NEUROPHARM.2021.108450","journal-title":"Neuropharmacology"},{"key":"16_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/bab.1568","volume":"65","author":"H Deng","year":"2018","unstructured":"Deng H, van der Stelt M (2018) Chemical tools to modulate 2-arachidonoylglycerol biosynthesis. Biotechnol Appl Biochem 65:9\u201315. https:\/\/doi.org\/10.1002\/bab.1568","journal-title":"Biotechnol Appl Biochem"},{"key":"16_CR6","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/IJO.2010.21","volume":"34","author":"LJ Aronne","year":"2010","unstructured":"Aronne LJ, Tonstad S, Moreno M, Gantz I, Erondu N, Suryawanshi S, Molony C, Sieberts S, Nayee J, Meehan AG et al (2010) A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obes (Lond) 34:919\u2013935. https:\/\/doi.org\/10.1038\/IJO.2010.21","journal-title":"Int J Obes (Lond)"},{"key":"16_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/157489008786264014","volume":"3","author":"A Samat","year":"2008","unstructured":"Samat A, Tomlinson B, Taheri S, Thomas GN (2008) Rimonabant for the treatment of obesity. Recent Pat Cardiovasc Drug Discov 3:187\u2013193. https:\/\/doi.org\/10.2174\/157489008786264014","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"16_CR8","doi-asserted-by":"publisher","unstructured":"Bisogno T, Mahadevan A, Coccurello R, Chang JW, Allar\u00e0 M, Chen Y, Giacovazzo G, Lichtman A, Cravatt B, Moles A et al (2012) Themed Section Cannabinoids. https:\/\/doi.org\/10.1111\/bph.2013.169.issue-4","DOI":"10.1111\/bph.2013.169.issue-4"},{"key":"16_CR9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1021\/acs.molpharmaceut.7b00657","volume":"15","author":"M Shin","year":"2018","unstructured":"Shin M, Snyder HW, Donvito G, Schurman LD, Fox TE, Lichtman AH, Kester M, Hsu KL (2018) Liposomal delivery of diacylglycerol lipase-beta inhibitors to macrophages dramatically enhances selectivity and efficacy in vivo. Mol Pharm 15:721\u2013728. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00657","journal-title":"Mol Pharm"},{"key":"16_CR10","doi-asserted-by":"publisher","unstructured":"Gregus AM, Buczynski MW Druggable targets in endocannabinoid signaling. https:\/\/doi.org\/10.1007\/978-3-030-50621-6_8","DOI":"10.1007\/978-3-030-50621-6_8"},{"key":"16_CR11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41589-020-0528-7","volume":"16","author":"ED Mock","year":"2020","unstructured":"Mock ED, Mustafa M, Gunduz-Cinar O, Cinar R, Petrie GN, Kantae V, Di X, Ogasawara D, Varga ZV, Paloczi J et al (2020) Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice. Nat Chem Biol 16:667\u2013675. https:\/\/doi.org\/10.1038\/s41589-020-0528-7","journal-title":"Nat Chem Biol"},{"key":"16_CR12","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1523\/JNEUROSCI.0583-07.2007","volume":"27","author":"T Trang","year":"2007","unstructured":"Trang T (2007) Inhibition of fatty acid amide hydrolase: a potential treatment for neuropathic pain. J Neurosci 27:3364\u20133365. https:\/\/doi.org\/10.1523\/JNEUROSCI.0583-07.2007","journal-title":"J Neurosci"},{"key":"16_CR13","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/J.1476-5381.2012.02179.X","volume":"167","author":"SG Woodhams","year":"2012","unstructured":"Woodhams SG, Wong A, Barrett DA, Bennett AJ, Chapman V, Alexander SPH (2012) Spinal administration of the monoacylglycerol lipase inhibitor JZL184 produces robust inhibitory effects on nociceptive processing and the development of central sensitization in the rat. Br J Pharmacol 167:1609\u20131619. https:\/\/doi.org\/10.1111\/J.1476-5381.2012.02179.X","journal-title":"Br J Pharmacol"},{"key":"16_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/nm803","volume":"9","author":"S Kathuria","year":"2002","unstructured":"Kathuria S, Gaetani S, Fegley D, Vali\u00f1o F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A et al (2002) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76\u201381. https:\/\/doi.org\/10.1038\/nm803","journal-title":"Nat Med"},{"key":"16_CR15","doi-asserted-by":"publisher","first-page":"20270","DOI":"10.1073\/PNAS.0909411106\/SUPPL_FILE\/SM3.MOV","volume":"106","author":"JZ Long","year":"2009","unstructured":"Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ, Lichtman AH, Wiley JL et al (2009) Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A 106:20270\u201320275. https:\/\/doi.org\/10.1073\/PNAS.0909411106\/SUPPL_FILE\/SM3.MOV","journal-title":"Proc Natl Acad Sci U S A"},{"key":"16_CR16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/J.BIOPSYCH.2011.04.022","volume":"70","author":"A Busquets-Garcia","year":"2011","unstructured":"Busquets-Garcia A, Puighermanal E, Pastor A, De La Torre R, Maldonado R, Ozaita A (2011) Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 70:479\u2013486. https:\/\/doi.org\/10.1016\/J.BIOPSYCH.2011.04.022","journal-title":"Biol Psychiatry"},{"key":"16_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41398-018-0141-7","volume":"8","author":"G Bedse","year":"2018","unstructured":"Bedse G, Bluett RJ, Patrick TA, Romness NK, Gaulden AD, Kingsley PJ, Plath N, Marnett LJ, Patel S (2018) Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors. Transl Psychiatry 8:92. https:\/\/doi.org\/10.1038\/s41398-018-0141-7","journal-title":"Transl Psychiatry"},{"key":"16_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/978-3-319-20825-1_9","volume":"231","author":"T Rubino","year":"2015","unstructured":"Rubino T, Zamberletti E, Parolaro D (2015) Endocannabinoids and Mental Disorders. Handb Exp Pharmacol 231:261\u2013283. https:\/\/doi.org\/10.1007\/978-3-319-20825-1_9","journal-title":"Handb Exp Pharmacol"},{"key":"16_CR19","doi-asserted-by":"publisher","unstructured":"Zhang Z, Wang W, Zhong P, Liu SJ, Long JZ, Zhao L, Gao H-Q, Cravatt BF, Liu Q-S Blockade of 2-arachidonoylglycerol hydrolysis produces antidepressant-like effects and enhances adult hippocampal neurogenesis and synaptic plasticity. Hippocampus. https:\/\/doi.org\/10.1002\/hipo.22344","DOI":"10.1002\/hipo.22344"},{"key":"16_CR20","doi-asserted-by":"crossref","unstructured":"Kaur R, Sidhu P, Singh S (2016) What failed BIA 10-2474 Phase I clinical trial? Global speculations and recommendations for future Phase I trials","DOI":"10.4103\/0976-500X.189661"},{"key":"16_CR21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/npp.2008.98","volume":"34","author":"V Micale","year":"2009","unstructured":"Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Drago F, Di Marzo V (2009) Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 34:593\u2013606. https:\/\/doi.org\/10.1038\/npp.2008.98","journal-title":"Neuropsychopharmacology"},{"key":"16_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.nrl.2016.11.008","volume":"34","author":"JM Viveros-Paredes","year":"2019","unstructured":"Viveros-Paredes JM, Gonzalez-Casta\u00f1eda RE, Escalante-Casta\u00f1eda A, Tejeda-Mart\u00ednez AR, Casta\u00f1eda-Achutigu\u00ed F, Flores-Soto ME (2019) Effect of inhibition of fatty acid amide hydrolase on MPTP-induced dopaminergic neuronal damage. Neurologia (Engl Ed) 34:143","journal-title":"Neurologia (Engl Ed)"},{"key":"16_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/J.NBD.2020.105157","volume":"147","author":"R Greco","year":"2021","unstructured":"Greco R, Demartini C, Zanaboni A, Casini I, De Icco R, Reggiani A, Misto A, Piomelli D, Tassorelli C (2021) Characterization of the peripheral FAAH inhibitor, URB937, in animal models of acute and chronic migraine. Neurobiol Dis 147:105157. https:\/\/doi.org\/10.1016\/J.NBD.2020.105157","journal-title":"Neurobiol Dis"},{"key":"16_CR24","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/S41598-018-20895-Z","volume":"8","author":"G Griebel","year":"2018","unstructured":"Griebel G, Stemmelin J, Lopez-Grancha M, Fauchey V, Slowinski F, Pichat P, Dargazanli G, Abouabdellah A, Cohen C, Bergis OE (2018) The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents. Sci Rep 8:2416. https:\/\/doi.org\/10.1038\/S41598-018-20895-Z","journal-title":"Sci Rep"},{"key":"16_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40268-016-0127-y","volume":"16","author":"S Pawsey","year":"2016","unstructured":"Pawsey S, Wood M, Browne H, Donaldson K, Christie M, Warrington S (2016) Safety, tolerability and pharmacokinetics of FAAH inhibitor V158866: a double-blind, randomised, placebo-controlled phase I study in healthy volunteers. Drugs R D 16:181. https:\/\/doi.org\/10.1007\/s40268-016-0127-y","journal-title":"Drugs R D"},{"key":"16_CR26","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/j.1365-2125.2011.04137.x","volume":"73","author":"GL Li","year":"2012","unstructured":"Li GL, Winter H, Arends R, Jay GW, Le V, Young T, Huggins JP (2012) Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. Br J Clin Pharmacol 73:706\u2013716. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04137.x","journal-title":"Br J Clin Pharmacol"},{"key":"16_CR27","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.lfs.2012.10.025.Therapeutic","volume":"92","author":"MM Mulvihill","year":"2014","unstructured":"Mulvihill MM, Nomura DK (2014) Therapeutic potential of MAGL inhibitors. Life Sci 92:492\u2013497. https:\/\/doi.org\/10.1016\/j.lfs.2012.10.025.Therapeutic","journal-title":"Life Sci"},{"key":"16_CR28","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/bph.2013.169.issue-4","volume":"169","author":"DM Kerr","year":"2012","unstructured":"Kerr DM, Harhen B, Okine BN, Egan LJ, Finn DP, Roche M, Roche M (2012) The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action. Br J Pharmacol 169:808. https:\/\/doi.org\/10.1111\/bph.2013.169.issue-4","journal-title":"Br J Pharmacol"},{"key":"16_CR29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/J.EBIOM.2019.05.048","volume":"44","author":"S Marino","year":"2019","unstructured":"Marino S, de Ridder D, Bishop RT, Renema N, Ponzetti M, Sophocleous A, Capulli M, Aljeffery A, Carrasco G, Gens MD et al (2019) Paradoxical effects of JZL184, an inhibitor of monoacylglycerol lipase, on bone remodelling in healthy and cancer-bearing mice. EBioMedicine 44:452\u2013466. https:\/\/doi.org\/10.1016\/J.EBIOM.2019.05.048","journal-title":"EBioMedicine"},{"key":"16_CR30","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/J.APSB.2019.10.006","volume":"10","author":"H Deng","year":"2020","unstructured":"Deng H, Li W (2020) Monoacylglycerol lipase inhibitors: modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders. Acta Pharm Sin B 10:582\u2013602. https:\/\/doi.org\/10.1016\/J.APSB.2019.10.006","journal-title":"Acta Pharm Sin B"},{"key":"16_CR31","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/NN.2616","volume":"13","author":"JE Schlosburg","year":"2010","unstructured":"Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, Nguyen PT, Ramesh D, Booker L, Burston JJ et al (2010) Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13:1113\u20131119. https:\/\/doi.org\/10.1038\/NN.2616","journal-title":"Nat Neurosci"},{"key":"16_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1055\/a-1675-3494","volume":"55","author":"AR Kirsten M\u00fcller-Vahl","year":"2022","unstructured":"Kirsten M\u00fcller-Vahl AR, Fremer C, Beals C, Ivkovic J, Loft H, Schindler C, Thieme Verlag GK, M\u00fcller-Vahl KR, M\u00fcller-Vahl KR et al (2022) Monoacylglycerol lipase inhibition in tourette syndrome \u2026 pharmacopsychiatry | endocannabinoid modulation using monoacylglycerol lipase inhibition in tourette syndrome: a phase 1 randomized, placebo-controlled study. Pharmacopsychiatry 55:148. https:\/\/doi.org\/10.1055\/a-1675-3494","journal-title":"Pharmacopsychiatry"},{"key":"16_CR33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/13543776.2021.1841166","volume":"31","author":"G Bononi","year":"2021","unstructured":"Bononi G, Poli G, Rizzolio F, Tuccinardi T, Macchia M, Minutolo F, Granchi C (2021) An updated patent review of monoacylglycerol lipase (MAGL) inhibitors (2018-present). Expert Opin Ther Pat 31:153\u2013168. https:\/\/doi.org\/10.1080\/13543776.2021.1841166","journal-title":"Expert Opin Ther Pat"},{"key":"16_CR34","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.chembiol.2009.05.004","volume":"16","author":"S Oddi","year":"2009","unstructured":"Oddi S, Fezza F, Pasquariello N, D\u2019Agostino A, Catanzaro G, De Simone C, Rapino C, Finazzi-Agr\u00f2 A, Maccarrone M (2009) Molecular identification of albumin and Hsp70 as cytosolic anandamide-binding proteins. Chem Biol 16:624\u2013632. https:\/\/doi.org\/10.1016\/j.chembiol.2009.05.004","journal-title":"Chem Biol"},{"key":"16_CR35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0009-3084(00)00191-2","volume":"108","author":"CJ Hillard","year":"2000","unstructured":"Hillard CJ, Jarrahian A (2000) The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem Phys Lipids 108:123\u2013134. https:\/\/doi.org\/10.1016\/S0009-3084(00)00191-2","journal-title":"Chem Phys Lipids"},{"key":"16_CR36","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.tibs.2010.05.008","volume":"35","author":"M Maccarrone","year":"2010","unstructured":"Maccarrone M, Dainese E, Oddi S (2010) Intracellular trafficking of anandamide: new concepts for signaling. Trends Biochem Sci 35:601\u2013608. https:\/\/doi.org\/10.1016\/j.tibs.2010.05.008","journal-title":"Trends Biochem Sci"},{"key":"16_CR37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/cells9030587","volume":"9","author":"Z Albakova","year":"2020","unstructured":"Albakova Z, Armeev GA, Kanevskiy LM, Kovalenko EI, Sapozhnikov AM (2020) HSP70 multi-functionality in cancer. Cells 9:587","journal-title":"Cells"},{"key":"16_CR38","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/iub.1682","volume":"69","author":"L Leboffe","year":"2017","unstructured":"Leboffe L, Di Masi A, Trezza V, Polticelli F, Ascenzi P (2017) Hypothesis human serum albumin: a modulator of cannabinoid drugs. IUBMB Life 69:834\u2013840. https:\/\/doi.org\/10.1002\/iub.1682","journal-title":"IUBMB Life"},{"key":"16_CR39","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrd2589","volume":"7","author":"F Masato","year":"2008","unstructured":"Masato F, Hotamisligil G\u00f6khan S (2008) Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 7:489. https:\/\/doi.org\/10.1038\/nrd2589","journal-title":"Nat Rev Drug Discov"},{"key":"16_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0094200","volume":"9","author":"M Kaczocha","year":"2014","unstructured":"Kaczocha M, Rebecchi MJ, Ralph BP, Teng YHG, Berger WT, Galbavy W, Elmes MW, Glaser ST, Wang L, Rizzo RC et al (2014) Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia. PLoS One 9:e94200. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0094200","journal-title":"PLoS One"},{"key":"16_CR41","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fpsyt.2016.00054","volume":"7","author":"M Lijffijt","year":"2016","unstructured":"Lijffijt M, Janiri L, Thanos PK, Clavin BH, Hamilton J, O\u2019rourke JR, Maher T, Koumas C, Miao E, Lankop J et al (2016) Examination of the addictive and behavioral properties of fatty acid-binding protein inhibitor sBFi26. Front Psychiatry 7:54. https:\/\/doi.org\/10.3389\/fpsyt.2016.00054","journal-title":"Front Psychiatry"},{"key":"16_CR42","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1586\/14750708.2.1.141","volume":"2","author":"N Battista","year":"2005","unstructured":"Battista N, Gasperi V, Fezza F, Maccarrone M (2005) The anandamide membrane transporter and the therapeutic implications of its inhibition. Therapy 2:141\u2013150. https:\/\/doi.org\/10.1586\/14750708.2.1.141","journal-title":"Therapy"},{"key":"16_CR43","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1126\/SCIENCE.277.5329.1094","volume":"277","author":"M Beltramo","year":"1997","unstructured":"Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277:1094\u20131097. https:\/\/doi.org\/10.1126\/SCIENCE.277.5329.1094","journal-title":"Science"},{"key":"16_CR44","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S0006-2952(03)00109-6","volume":"65","author":"G Ortar","year":"2003","unstructured":"Ortar G, Ligresti A, De Petrocellis L, Morera E, Di Marzo V (2003) Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol 65:1473\u20131481. https:\/\/doi.org\/10.1016\/S0006-2952(03)00109-6","journal-title":"Biochem Pharmacol"},{"key":"16_CR45","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1021\/jm015545y","volume":"44","author":"ML L\u00f3pez-Rodr\u00edguez","year":"2001","unstructured":"L\u00f3pez-Rodr\u00edguez ML, Viso A, Ortega-Guti\u00e9rrez S, Lastres-Becker I, Gonz\u00e1lez S, Fern\u00e1ndez-Ruiz J, Ramos JA (2001) Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. J Med Chem 44:4505\u20134508. https:\/\/doi.org\/10.1021\/jm015545y","journal-title":"J Med Chem"},{"key":"16_CR46","doi-asserted-by":"publisher","first-page":"9699","DOI":"10.1021\/JA062999H","volume":"128","author":"JP Alexander","year":"2006","unstructured":"Alexander JP, Cravatt BF (2006) The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J Am Chem Soc 128:9699\u20139704. https:\/\/doi.org\/10.1021\/JA062999H","journal-title":"J Am Chem Soc"},{"key":"16_CR47","doi-asserted-by":"publisher","first-page":"8756","DOI":"10.1073\/PNAS.0400997101\/ASSET\/0CB214B2-5868-4FF0-A16A-AA02004FD430\/ASSETS\/GRAPHIC\/ZPQ0210449340005.JPEG","volume":"101","author":"D Fegley","year":"2004","unstructured":"Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A, Piomelli D (2004) Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci U S A 101:8756\u20138761. https:\/\/doi.org\/10.1073\/PNAS.0400997101\/ASSET\/0CB214B2-5868-4FF0-A16A-AA02004FD430\/ASSETS\/GRAPHIC\/ZPQ0210449340005.JPEG","journal-title":"Proc Natl Acad Sci U S A"},{"key":"16_CR48","doi-asserted-by":"publisher","first-page":"E5006","DOI":"10.1073\/PNAS.1704065114\/-\/DCSUPPLEMENTAL","volume":"114","author":"A Chicca","year":"2017","unstructured":"Chicca A, Nicolussi S, Bartholom\u00e4us R, Blunder M, Rey AA, Petrucci V, Reynoso-Moreno IDC, Viveros-Paredes JM, Gens MD, Lutz B et al (2017) Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake. Proc Natl Acad Sci U S A 114:E5006\u2013E5015. https:\/\/doi.org\/10.1073\/PNAS.1704065114\/-\/DCSUPPLEMENTAL","journal-title":"Proc Natl Acad Sci U S A"},{"key":"16_CR49","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1021\/ACSPTSCI.0C00214","volume":"4","author":"I Reynoso-Moreno","year":"2021","unstructured":"Reynoso-Moreno I, Tietz S, Vallini E, Engelhardt B, Gertsch J, Chicca A (2021) Selective endocannabinoid reuptake inhibitor WOBE437 reduces disease progression in a mouse model of multiple sclerosis. ACS Pharmacol Transl Sci 4:765\u2013779. https:\/\/doi.org\/10.1021\/ACSPTSCI.0C00214","journal-title":"ACS Pharmacol Transl Sci"},{"key":"16_CR50","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/FNMOL.2018.00180\/BIBTEX","volume":"11","author":"I Reynoso-Moreno","year":"2018","unstructured":"Reynoso-Moreno I, Chicca A, Flores-Soto ME, Viveros-Paredes JM, Gertsch J (2018) The endocannabinoid reuptake inhibitor WOBE437 is orally bioavailable and exerts indirect polypharmacological effects via different endocannabinoid receptors. Front Mol Neurosci 11:180. https:\/\/doi.org\/10.3389\/FNMOL.2018.00180\/BIBTEX","journal-title":"Front Mol Neurosci"}],"container-title":["Methods in Molecular Biology","Endocannabinoid Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2728-0_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T13:12:44Z","timestamp":1664025164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2728-0_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,25]]},"ISBN":["9781071627273","9781071627280"],"references-count":50,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2728-0_16","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,25]]},"assertion":[{"value":"25 September 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}